Drug Class Description
Antimycotics for systemic use
Generic Name
Caspofungin
Drug Description
CANCIDAS 50 mg Powder for concentrate for solution for infusion: Each vial contains 50 mg caspofungin (as acetate). Each 50 mg vial contains 35.7 mg of sucrose.CANCIDAS 70 mg Powder for concentrate for solution for infusion: Each vial contains 70 mg caspofungin (as acetate). Each 70 mg vial contains 50.0 mg of sucrose.
Presentation
Powder for concentrate for solution for infusion.White to offwhite compact, lyophilised powder
Indications
• Treatment of invasive candidiasis in adult or paediatric patients.
• Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.
• Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients.
Adult Dosage
CANCIDAS should be initiated by a physician experienced in the management of invasive fungal infections.
After reconstitution and dilution, the solution should be administered by slow intravenous infusion over approximately 1 hour. Do not mix or co-infuse CANCIDAS with other medicines, as there are no data available on the compatibility of CANCIDAS with other intravenous substances, additives, or medicinal products. DO NOT USE DILUENTS CONTAINING GLUCOSE, as CANCIDAS is not stable in diluents containing glucose. For reconstitution directions see section 6.6.
Both 70 mg and 50 mg vials are available.
CANCIDAS should be given as a single daily infusion.
Dosage in adult patients
